nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—CYP3A7—Sorafenib—thyroid cancer	0.109	0.182	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Sorafenib—thyroid cancer	0.109	0.182	CbGbCtD
Ondansetron—CYP3A5—Sorafenib—thyroid cancer	0.0817	0.136	CbGbCtD
Ondansetron—CYP1A2—Sorafenib—thyroid cancer	0.0608	0.101	CbGbCtD
Ondansetron—CYP2C9—Sorafenib—thyroid cancer	0.0548	0.0914	CbGbCtD
Ondansetron—CYP3A4—Vandetanib—thyroid cancer	0.0528	0.0881	CbGbCtD
Ondansetron—CYP2D6—Sorafenib—thyroid cancer	0.0501	0.0835	CbGbCtD
Ondansetron—CYP3A4—Sorafenib—thyroid cancer	0.0319	0.0531	CbGbCtD
Ondansetron—CYP2D6—Doxorubicin—thyroid cancer	0.0304	0.0507	CbGbCtD
Ondansetron—CYP3A4—Doxorubicin—thyroid cancer	0.0193	0.0322	CbGbCtD
Ondansetron—Hepatobiliary disease—Vandetanib—thyroid cancer	0.00259	0.00789	CcSEcCtD
Ondansetron—Bradycardia—Vandetanib—thyroid cancer	0.0025	0.00763	CcSEcCtD
Ondansetron—Haemoglobin—Vandetanib—thyroid cancer	0.00247	0.00753	CcSEcCtD
Ondansetron—Haemorrhage—Vandetanib—thyroid cancer	0.00245	0.00749	CcSEcCtD
Ondansetron—Visual impairment—Vandetanib—thyroid cancer	0.00236	0.00722	CcSEcCtD
Ondansetron—Erythema multiforme—Vandetanib—thyroid cancer	0.00232	0.00709	CcSEcCtD
Ondansetron—Eye disorder—Vandetanib—thyroid cancer	0.00229	0.007	CcSEcCtD
Ondansetron—Cardiac disorder—Vandetanib—thyroid cancer	0.00228	0.00695	CcSEcCtD
Ondansetron—Anorectal discomfort—Epirubicin—thyroid cancer	0.00223	0.0068	CcSEcCtD
Ondansetron—Angiopathy—Vandetanib—thyroid cancer	0.00223	0.0068	CcSEcCtD
Ondansetron—Mediastinal disorder—Vandetanib—thyroid cancer	0.00221	0.00675	CcSEcCtD
Ondansetron—Local reaction—Epirubicin—thyroid cancer	0.0022	0.00672	CcSEcCtD
Ondansetron—Blindness—Epirubicin—thyroid cancer	0.0022	0.00672	CcSEcCtD
Ondansetron—Arrhythmia—Vandetanib—thyroid cancer	0.00219	0.00669	CcSEcCtD
Ondansetron—Hypokalaemia—Sorafenib—thyroid cancer	0.00218	0.00665	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Sorafenib—thyroid cancer	0.00215	0.00658	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Sorafenib—thyroid cancer	0.00215	0.00658	CcSEcCtD
Ondansetron—Anorectal discomfort—Doxorubicin—thyroid cancer	0.00206	0.0063	CcSEcCtD
Ondansetron—Blindness—Doxorubicin—thyroid cancer	0.00204	0.00622	CcSEcCtD
Ondansetron—Local reaction—Doxorubicin—thyroid cancer	0.00204	0.00622	CcSEcCtD
Ondansetron—Vision blurred—Vandetanib—thyroid cancer	0.00201	0.00615	CcSEcCtD
Ondansetron—Tremor—Vandetanib—thyroid cancer	0.002	0.00611	CcSEcCtD
Ondansetron—Loss of consciousness—Vandetanib—thyroid cancer	0.00188	0.00573	CcSEcCtD
Ondansetron—Cough—Vandetanib—thyroid cancer	0.00186	0.00569	CcSEcCtD
Ondansetron—Convulsion—Vandetanib—thyroid cancer	0.00185	0.00565	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00183	0.00558	CcSEcCtD
Ondansetron—Chest pain—Vandetanib—thyroid cancer	0.00182	0.00555	CcSEcCtD
Ondansetron—Acute coronary syndrome—Sorafenib—thyroid cancer	0.00182	0.00555	CcSEcCtD
Ondansetron—Anxiety—Vandetanib—thyroid cancer	0.00181	0.00553	CcSEcCtD
Ondansetron—Myocardial infarction—Sorafenib—thyroid cancer	0.00181	0.00552	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00181	0.00552	CcSEcCtD
Ondansetron—Redness—Epirubicin—thyroid cancer	0.0018	0.00551	CcSEcCtD
Ondansetron—Dry mouth—Vandetanib—thyroid cancer	0.00178	0.00543	CcSEcCtD
Ondansetron—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00174	0.00533	CcSEcCtD
Ondansetron—Nervous system disorder—Vandetanib—thyroid cancer	0.00171	0.00522	CcSEcCtD
Ondansetron—Skin disorder—Vandetanib—thyroid cancer	0.00169	0.00517	CcSEcCtD
Ondansetron—Redness—Doxorubicin—thyroid cancer	0.00167	0.0051	CcSEcCtD
Ondansetron—Haemoglobin—Sorafenib—thyroid cancer	0.00166	0.00508	CcSEcCtD
Ondansetron—Haemorrhage—Sorafenib—thyroid cancer	0.00166	0.00506	CcSEcCtD
Ondansetron—Paraesthesia—Vandetanib—thyroid cancer	0.00157	0.00478	CcSEcCtD
Ondansetron—Erythema multiforme—Sorafenib—thyroid cancer	0.00157	0.00478	CcSEcCtD
Ondansetron—Dyspnoea—Vandetanib—thyroid cancer	0.00155	0.00475	CcSEcCtD
Ondansetron—Feeling hot—Epirubicin—thyroid cancer	0.00155	0.00474	CcSEcCtD
Ondansetron—Flushing—Sorafenib—thyroid cancer	0.00154	0.00469	CcSEcCtD
Ondansetron—Cardiac disorder—Sorafenib—thyroid cancer	0.00154	0.00469	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00151	0.0046	CcSEcCtD
Ondansetron—Fatigue—Vandetanib—thyroid cancer	0.0015	0.00459	CcSEcCtD
Ondansetron—Angiopathy—Sorafenib—thyroid cancer	0.0015	0.00459	CcSEcCtD
Ondansetron—Immune system disorder—Sorafenib—thyroid cancer	0.0015	0.00457	CcSEcCtD
Ondansetron—Injection site pain—Epirubicin—thyroid cancer	0.00149	0.00456	CcSEcCtD
Ondansetron—Mediastinal disorder—Sorafenib—thyroid cancer	0.00149	0.00456	CcSEcCtD
Ondansetron—Constipation—Vandetanib—thyroid cancer	0.00149	0.00455	CcSEcCtD
Ondansetron—Pain—Vandetanib—thyroid cancer	0.00149	0.00455	CcSEcCtD
Ondansetron—Arrhythmia—Sorafenib—thyroid cancer	0.00148	0.00452	CcSEcCtD
Ondansetron—Erythema—Sorafenib—thyroid cancer	0.00144	0.0044	CcSEcCtD
Ondansetron—Feeling hot—Doxorubicin—thyroid cancer	0.00144	0.00439	CcSEcCtD
Ondansetron—Neoplasm malignant—Epirubicin—thyroid cancer	0.00143	0.00436	CcSEcCtD
Ondansetron—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00143	0.00435	CcSEcCtD
Ondansetron—Cardiovascular disorder—Epirubicin—thyroid cancer	0.00139	0.00423	CcSEcCtD
Ondansetron—Injection site pain—Doxorubicin—thyroid cancer	0.00138	0.00422	CcSEcCtD
Ondansetron—Abdominal pain—Vandetanib—thyroid cancer	0.00138	0.00421	CcSEcCtD
Ondansetron—Body temperature increased—Vandetanib—thyroid cancer	0.00138	0.00421	CcSEcCtD
Ondansetron—Ventricular extrasystoles—Epirubicin—thyroid cancer	0.00135	0.00412	CcSEcCtD
Ondansetron—Neoplasm malignant—Doxorubicin—thyroid cancer	0.00132	0.00403	CcSEcCtD
Ondansetron—Angioedema—Sorafenib—thyroid cancer	0.00132	0.00402	CcSEcCtD
Ondansetron—Dyskinesia—Epirubicin—thyroid cancer	0.0013	0.00396	CcSEcCtD
Ondansetron—Syncope—Sorafenib—thyroid cancer	0.00129	0.00395	CcSEcCtD
Ondansetron—Cardiovascular disorder—Doxorubicin—thyroid cancer	0.00128	0.00392	CcSEcCtD
Ondansetron—Loss of consciousness—Sorafenib—thyroid cancer	0.00127	0.00387	CcSEcCtD
Ondansetron—Cough—Sorafenib—thyroid cancer	0.00126	0.00384	CcSEcCtD
Ondansetron—Asthenia—Vandetanib—thyroid cancer	0.00125	0.00382	CcSEcCtD
Ondansetron—Ventricular extrasystoles—Doxorubicin—thyroid cancer	0.00125	0.00381	CcSEcCtD
Ondansetron—Pruritus—Vandetanib—thyroid cancer	0.00123	0.00377	CcSEcCtD
Ondansetron—Musculoskeletal pain—Epirubicin—thyroid cancer	0.00123	0.00377	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00122	0.00372	CcSEcCtD
Ondansetron—Hepatocellular injury—Epirubicin—thyroid cancer	0.00122	0.00372	CcSEcCtD
Ondansetron—Hiccups—Epirubicin—thyroid cancer	0.00122	0.00372	CcSEcCtD
Ondansetron—Injection site reaction—Epirubicin—thyroid cancer	0.00121	0.0037	CcSEcCtD
Ondansetron—Dry mouth—Sorafenib—thyroid cancer	0.0012	0.00366	CcSEcCtD
Ondansetron—Dyskinesia—Doxorubicin—thyroid cancer	0.0012	0.00366	CcSEcCtD
Ondansetron—Diarrhoea—Vandetanib—thyroid cancer	0.00119	0.00364	CcSEcCtD
Ondansetron—Anaphylactic shock—Sorafenib—thyroid cancer	0.00118	0.00359	CcSEcCtD
Ondansetron—Shock—Sorafenib—thyroid cancer	0.00116	0.00353	CcSEcCtD
Ondansetron—Nervous system disorder—Sorafenib—thyroid cancer	0.00115	0.00352	CcSEcCtD
Ondansetron—Dizziness—Vandetanib—thyroid cancer	0.00115	0.00352	CcSEcCtD
Ondansetron—Skin disorder—Sorafenib—thyroid cancer	0.00114	0.00349	CcSEcCtD
Ondansetron—Musculoskeletal pain—Doxorubicin—thyroid cancer	0.00114	0.00348	CcSEcCtD
Ondansetron—Hepatocellular injury—Doxorubicin—thyroid cancer	0.00113	0.00344	CcSEcCtD
Ondansetron—Hiccups—Doxorubicin—thyroid cancer	0.00113	0.00344	CcSEcCtD
Ondansetron—Injection site reaction—Doxorubicin—thyroid cancer	0.00112	0.00342	CcSEcCtD
Ondansetron—Vomiting—Vandetanib—thyroid cancer	0.00111	0.00339	CcSEcCtD
Ondansetron—Rash—Vandetanib—thyroid cancer	0.0011	0.00336	CcSEcCtD
Ondansetron—Dermatitis—Vandetanib—thyroid cancer	0.0011	0.00335	CcSEcCtD
Ondansetron—Headache—Vandetanib—thyroid cancer	0.00109	0.00334	CcSEcCtD
Ondansetron—Dyspnoea—Sorafenib—thyroid cancer	0.00105	0.0032	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00102	0.0031	CcSEcCtD
Ondansetron—Fatigue—Sorafenib—thyroid cancer	0.00101	0.0031	CcSEcCtD
Ondansetron—Constipation—Sorafenib—thyroid cancer	0.00101	0.00307	CcSEcCtD
Ondansetron—Pain—Sorafenib—thyroid cancer	0.00101	0.00307	CcSEcCtD
Ondansetron—Hepatic failure—Epirubicin—thyroid cancer	0.000984	0.003	CcSEcCtD
Ondansetron—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000962	0.00294	CcSEcCtD
Ondansetron—Urticaria—Sorafenib—thyroid cancer	0.000934	0.00285	CcSEcCtD
Ondansetron—Abdominal pain—Sorafenib—thyroid cancer	0.00093	0.00284	CcSEcCtD
Ondansetron—Body temperature increased—Sorafenib—thyroid cancer	0.00093	0.00284	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.000914	0.00279	CcSEcCtD
Ondansetron—Hepatic failure—Doxorubicin—thyroid cancer	0.00091	0.00278	CcSEcCtD
Ondansetron—Hypersensitivity—Sorafenib—thyroid cancer	0.000866	0.00265	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.000845	0.00258	CcSEcCtD
Ondansetron—Asthenia—Sorafenib—thyroid cancer	0.000844	0.00258	CcSEcCtD
Ondansetron—Pruritus—Sorafenib—thyroid cancer	0.000832	0.00254	CcSEcCtD
Ondansetron—Liver function test abnormal—Epirubicin—thyroid cancer	0.000816	0.00249	CcSEcCtD
Ondansetron—Hypokalaemia—Epirubicin—thyroid cancer	0.000805	0.00246	CcSEcCtD
Ondansetron—Diarrhoea—Sorafenib—thyroid cancer	0.000805	0.00246	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000796	0.00243	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000796	0.00243	CcSEcCtD
Ondansetron—Dizziness—Sorafenib—thyroid cancer	0.000778	0.00237	CcSEcCtD
Ondansetron—Asthma—Epirubicin—thyroid cancer	0.000764	0.00233	CcSEcCtD
Ondansetron—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000755	0.00231	CcSEcCtD
Ondansetron—Vomiting—Sorafenib—thyroid cancer	0.000748	0.00228	CcSEcCtD
Ondansetron—Hypokalaemia—Doxorubicin—thyroid cancer	0.000745	0.00227	CcSEcCtD
Ondansetron—Angina pectoris—Epirubicin—thyroid cancer	0.000744	0.00227	CcSEcCtD
Ondansetron—Rash—Sorafenib—thyroid cancer	0.000741	0.00226	CcSEcCtD
Ondansetron—Dermatitis—Sorafenib—thyroid cancer	0.000741	0.00226	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000737	0.00225	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000737	0.00225	CcSEcCtD
Ondansetron—Headache—Sorafenib—thyroid cancer	0.000737	0.00225	CcSEcCtD
Ondansetron—Dysuria—Epirubicin—thyroid cancer	0.000715	0.00218	CcSEcCtD
Ondansetron—Asthma—Doxorubicin—thyroid cancer	0.000707	0.00216	CcSEcCtD
Ondansetron—Angina pectoris—Doxorubicin—thyroid cancer	0.000689	0.0021	CcSEcCtD
Ondansetron—Drowsiness—Epirubicin—thyroid cancer	0.000681	0.00208	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000676	0.00206	CcSEcCtD
Ondansetron—Urinary tract infection—Epirubicin—thyroid cancer	0.000662	0.00202	CcSEcCtD
Ondansetron—Dysuria—Doxorubicin—thyroid cancer	0.000661	0.00202	CcSEcCtD
Ondansetron—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000644	0.00197	CcSEcCtD
Ondansetron—Drowsiness—Doxorubicin—thyroid cancer	0.000631	0.00193	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000625	0.00191	CcSEcCtD
Ondansetron—Bradycardia—Epirubicin—thyroid cancer	0.000623	0.0019	CcSEcCtD
Ondansetron—Haemoglobin—Epirubicin—thyroid cancer	0.000615	0.00188	CcSEcCtD
Ondansetron—Urinary tract infection—Doxorubicin—thyroid cancer	0.000613	0.00187	CcSEcCtD
Ondansetron—Haemorrhage—Epirubicin—thyroid cancer	0.000612	0.00187	CcSEcCtD
Ondansetron—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000596	0.00182	CcSEcCtD
Ondansetron—Visual impairment—Epirubicin—thyroid cancer	0.00059	0.0018	CcSEcCtD
Ondansetron—Erythema multiforme—Epirubicin—thyroid cancer	0.000578	0.00177	CcSEcCtD
Ondansetron—Bradycardia—Doxorubicin—thyroid cancer	0.000576	0.00176	CcSEcCtD
Ondansetron—Eye disorder—Epirubicin—thyroid cancer	0.000572	0.00175	CcSEcCtD
Ondansetron—Haemoglobin—Doxorubicin—thyroid cancer	0.000569	0.00174	CcSEcCtD
Ondansetron—Cardiac disorder—Epirubicin—thyroid cancer	0.000568	0.00173	CcSEcCtD
Ondansetron—Flushing—Epirubicin—thyroid cancer	0.000568	0.00173	CcSEcCtD
Ondansetron—Haemorrhage—Doxorubicin—thyroid cancer	0.000566	0.00173	CcSEcCtD
Ondansetron—Angiopathy—Epirubicin—thyroid cancer	0.000555	0.00169	CcSEcCtD
Ondansetron—Immune system disorder—Epirubicin—thyroid cancer	0.000553	0.00169	CcSEcCtD
Ondansetron—Mediastinal disorder—Epirubicin—thyroid cancer	0.000551	0.00168	CcSEcCtD
Ondansetron—Chills—Epirubicin—thyroid cancer	0.000549	0.00168	CcSEcCtD
Ondansetron—Arrhythmia—Epirubicin—thyroid cancer	0.000546	0.00167	CcSEcCtD
Ondansetron—Visual impairment—Doxorubicin—thyroid cancer	0.000545	0.00167	CcSEcCtD
Ondansetron—Erythema multiforme—Doxorubicin—thyroid cancer	0.000535	0.00163	CcSEcCtD
Ondansetron—Erythema—Epirubicin—thyroid cancer	0.000533	0.00163	CcSEcCtD
Ondansetron—Eye disorder—Doxorubicin—thyroid cancer	0.000529	0.00162	CcSEcCtD
Ondansetron—Flushing—Doxorubicin—thyroid cancer	0.000525	0.0016	CcSEcCtD
Ondansetron—Cardiac disorder—Doxorubicin—thyroid cancer	0.000525	0.0016	CcSEcCtD
Ondansetron—Flatulence—Epirubicin—thyroid cancer	0.000525	0.0016	CcSEcCtD
Ondansetron—Angiopathy—Doxorubicin—thyroid cancer	0.000514	0.00157	CcSEcCtD
Ondansetron—Immune system disorder—Doxorubicin—thyroid cancer	0.000511	0.00156	CcSEcCtD
Ondansetron—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00051	0.00156	CcSEcCtD
Ondansetron—Chills—Doxorubicin—thyroid cancer	0.000508	0.00155	CcSEcCtD
Ondansetron—Arrhythmia—Doxorubicin—thyroid cancer	0.000506	0.00154	CcSEcCtD
Ondansetron—Vision blurred—Epirubicin—thyroid cancer	0.000502	0.00153	CcSEcCtD
Ondansetron—Ill-defined disorder—Epirubicin—thyroid cancer	0.000494	0.00151	CcSEcCtD
Ondansetron—Erythema—Doxorubicin—thyroid cancer	0.000493	0.0015	CcSEcCtD
Ondansetron—Agitation—Epirubicin—thyroid cancer	0.000489	0.00149	CcSEcCtD
Ondansetron—Flatulence—Doxorubicin—thyroid cancer	0.000486	0.00148	CcSEcCtD
Ondansetron—Malaise—Epirubicin—thyroid cancer	0.00048	0.00147	CcSEcCtD
Ondansetron—Syncope—Epirubicin—thyroid cancer	0.000478	0.00146	CcSEcCtD
Ondansetron—Palpitations—Epirubicin—thyroid cancer	0.000471	0.00144	CcSEcCtD
Ondansetron—Loss of consciousness—Epirubicin—thyroid cancer	0.000468	0.00143	CcSEcCtD
Ondansetron—Cough—Epirubicin—thyroid cancer	0.000465	0.00142	CcSEcCtD
Ondansetron—Vision blurred—Doxorubicin—thyroid cancer	0.000464	0.00142	CcSEcCtD
Ondansetron—Convulsion—Epirubicin—thyroid cancer	0.000461	0.00141	CcSEcCtD
Ondansetron—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000457	0.0014	CcSEcCtD
Ondansetron—Chest pain—Epirubicin—thyroid cancer	0.000453	0.00138	CcSEcCtD
Ondansetron—Agitation—Doxorubicin—thyroid cancer	0.000453	0.00138	CcSEcCtD
Ondansetron—Anxiety—Epirubicin—thyroid cancer	0.000452	0.00138	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00045	0.00138	CcSEcCtD
Ondansetron—Discomfort—Epirubicin—thyroid cancer	0.000448	0.00137	CcSEcCtD
Ondansetron—Malaise—Doxorubicin—thyroid cancer	0.000444	0.00136	CcSEcCtD
Ondansetron—Dry mouth—Epirubicin—thyroid cancer	0.000443	0.00135	CcSEcCtD
Ondansetron—Syncope—Doxorubicin—thyroid cancer	0.000442	0.00135	CcSEcCtD
Ondansetron—Palpitations—Doxorubicin—thyroid cancer	0.000435	0.00133	CcSEcCtD
Ondansetron—Anaphylactic shock—Epirubicin—thyroid cancer	0.000435	0.00133	CcSEcCtD
Ondansetron—Loss of consciousness—Doxorubicin—thyroid cancer	0.000433	0.00132	CcSEcCtD
Ondansetron—Cough—Doxorubicin—thyroid cancer	0.00043	0.00131	CcSEcCtD
Ondansetron—Shock—Epirubicin—thyroid cancer	0.000428	0.00131	CcSEcCtD
Ondansetron—Convulsion—Doxorubicin—thyroid cancer	0.000427	0.0013	CcSEcCtD
Ondansetron—Nervous system disorder—Epirubicin—thyroid cancer	0.000426	0.0013	CcSEcCtD
Ondansetron—Tachycardia—Epirubicin—thyroid cancer	0.000424	0.0013	CcSEcCtD
Ondansetron—Skin disorder—Epirubicin—thyroid cancer	0.000422	0.00129	CcSEcCtD
Ondansetron—Chest pain—Doxorubicin—thyroid cancer	0.000419	0.00128	CcSEcCtD
Ondansetron—Anxiety—Doxorubicin—thyroid cancer	0.000418	0.00128	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000417	0.00127	CcSEcCtD
Ondansetron—Discomfort—Doxorubicin—thyroid cancer	0.000414	0.00127	CcSEcCtD
Ondansetron—Dry mouth—Doxorubicin—thyroid cancer	0.00041	0.00125	CcSEcCtD
Ondansetron—Hypotension—Epirubicin—thyroid cancer	0.000406	0.00124	CcSEcCtD
Ondansetron—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000402	0.00123	CcSEcCtD
Ondansetron—Shock—Doxorubicin—thyroid cancer	0.000396	0.00121	CcSEcCtD
Ondansetron—Nervous system disorder—Doxorubicin—thyroid cancer	0.000394	0.0012	CcSEcCtD
Ondansetron—Tachycardia—Doxorubicin—thyroid cancer	0.000392	0.0012	CcSEcCtD
Ondansetron—Skin disorder—Doxorubicin—thyroid cancer	0.000391	0.00119	CcSEcCtD
Ondansetron—Paraesthesia—Epirubicin—thyroid cancer	0.00039	0.00119	CcSEcCtD
Ondansetron—Dyspnoea—Epirubicin—thyroid cancer	0.000387	0.00118	CcSEcCtD
Ondansetron—Somnolence—Epirubicin—thyroid cancer	0.000386	0.00118	CcSEcCtD
Ondansetron—Hypotension—Doxorubicin—thyroid cancer	0.000376	0.00115	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000375	0.00115	CcSEcCtD
Ondansetron—Fatigue—Epirubicin—thyroid cancer	0.000375	0.00114	CcSEcCtD
Ondansetron—Pain—Epirubicin—thyroid cancer	0.000372	0.00114	CcSEcCtD
Ondansetron—Constipation—Epirubicin—thyroid cancer	0.000372	0.00114	CcSEcCtD
Ondansetron—Paraesthesia—Doxorubicin—thyroid cancer	0.000361	0.0011	CcSEcCtD
Ondansetron—Dyspnoea—Doxorubicin—thyroid cancer	0.000359	0.00109	CcSEcCtD
Ondansetron—Feeling abnormal—Epirubicin—thyroid cancer	0.000358	0.00109	CcSEcCtD
Ondansetron—Somnolence—Doxorubicin—thyroid cancer	0.000358	0.00109	CcSEcCtD
Ondansetron—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000355	0.00109	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000347	0.00106	CcSEcCtD
Ondansetron—Fatigue—Doxorubicin—thyroid cancer	0.000347	0.00106	CcSEcCtD
Ondansetron—Urticaria—Epirubicin—thyroid cancer	0.000345	0.00105	CcSEcCtD
Ondansetron—Pain—Doxorubicin—thyroid cancer	0.000344	0.00105	CcSEcCtD
Ondansetron—Constipation—Doxorubicin—thyroid cancer	0.000344	0.00105	CcSEcCtD
Ondansetron—Abdominal pain—Epirubicin—thyroid cancer	0.000344	0.00105	CcSEcCtD
Ondansetron—Body temperature increased—Epirubicin—thyroid cancer	0.000344	0.00105	CcSEcCtD
Ondansetron—Feeling abnormal—Doxorubicin—thyroid cancer	0.000331	0.00101	CcSEcCtD
Ondansetron—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000329	0.001	CcSEcCtD
Ondansetron—Hypersensitivity—Epirubicin—thyroid cancer	0.00032	0.000978	CcSEcCtD
Ondansetron—Urticaria—Doxorubicin—thyroid cancer	0.000319	0.000976	CcSEcCtD
Ondansetron—Abdominal pain—Doxorubicin—thyroid cancer	0.000318	0.000971	CcSEcCtD
Ondansetron—Body temperature increased—Doxorubicin—thyroid cancer	0.000318	0.000971	CcSEcCtD
Ondansetron—Asthenia—Epirubicin—thyroid cancer	0.000312	0.000952	CcSEcCtD
Ondansetron—Pruritus—Epirubicin—thyroid cancer	0.000307	0.000939	CcSEcCtD
Ondansetron—Diarrhoea—Epirubicin—thyroid cancer	0.000297	0.000908	CcSEcCtD
Ondansetron—Hypersensitivity—Doxorubicin—thyroid cancer	0.000296	0.000905	CcSEcCtD
Ondansetron—Asthenia—Doxorubicin—thyroid cancer	0.000289	0.000881	CcSEcCtD
Ondansetron—Dizziness—Epirubicin—thyroid cancer	0.000287	0.000878	CcSEcCtD
Ondansetron—Pruritus—Doxorubicin—thyroid cancer	0.000285	0.000869	CcSEcCtD
Ondansetron—Vomiting—Epirubicin—thyroid cancer	0.000276	0.000844	CcSEcCtD
Ondansetron—Diarrhoea—Doxorubicin—thyroid cancer	0.000275	0.00084	CcSEcCtD
Ondansetron—Rash—Epirubicin—thyroid cancer	0.000274	0.000837	CcSEcCtD
Ondansetron—Dermatitis—Epirubicin—thyroid cancer	0.000274	0.000836	CcSEcCtD
Ondansetron—Headache—Epirubicin—thyroid cancer	0.000272	0.000831	CcSEcCtD
Ondansetron—Dizziness—Doxorubicin—thyroid cancer	0.000266	0.000812	CcSEcCtD
Ondansetron—Vomiting—Doxorubicin—thyroid cancer	0.000256	0.000781	CcSEcCtD
Ondansetron—Rash—Doxorubicin—thyroid cancer	0.000254	0.000774	CcSEcCtD
Ondansetron—Dermatitis—Doxorubicin—thyroid cancer	0.000253	0.000774	CcSEcCtD
Ondansetron—Headache—Doxorubicin—thyroid cancer	0.000252	0.000769	CcSEcCtD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000159	0.00218	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—SST—thyroid cancer	0.000159	0.00218	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—TSHR—thyroid cancer	0.000156	0.00213	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—PTCH1—thyroid cancer	0.000153	0.0021	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—CALCA—thyroid cancer	0.000153	0.0021	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—MINPP1—thyroid cancer	0.000152	0.00208	CbGpPWpGaD
Ondansetron—CYP2E1—Biological oxidations—RXRA—thyroid cancer	0.00015	0.00205	CbGpPWpGaD
Ondansetron—CYP3A5—Biological oxidations—RXRA—thyroid cancer	0.00015	0.00205	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—TSHR—thyroid cancer	0.000148	0.00203	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—PRKAR1A—thyroid cancer	0.000146	0.002	CbGpPWpGaD
Ondansetron—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000141	0.00193	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—SST—thyroid cancer	0.00014	0.00192	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—MEN1—thyroid cancer	0.000139	0.00191	CbGpPWpGaD
Ondansetron—KCNH2—Neuronal System—BRAF—thyroid cancer	0.000138	0.00189	CbGpPWpGaD
Ondansetron—OPRM1—IL4-mediated signaling events—AKT1—thyroid cancer	0.000136	0.00186	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—CALCA—thyroid cancer	0.000135	0.00185	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CALCB—thyroid cancer	0.000134	0.00183	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—PTCH1—thyroid cancer	0.000132	0.00181	CbGpPWpGaD
Ondansetron—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000131	0.00179	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—NDUFA13—thyroid cancer	0.000129	0.00177	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.000128	0.00176	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TRIM33—thyroid cancer	0.000127	0.00174	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—PTCH1—thyroid cancer	0.000126	0.00173	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—CHST14—thyroid cancer	0.000121	0.00167	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—SST—thyroid cancer	0.000121	0.00166	CbGpPWpGaD
Ondansetron—CYP1A2—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.00012	0.00165	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CALCB—thyroid cancer	0.000118	0.00162	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—CALCA—thyroid cancer	0.000117	0.0016	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—TSHR—thyroid cancer	0.000115	0.00158	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—SST—thyroid cancer	0.000115	0.00158	CbGpPWpGaD
Ondansetron—OPRM1—TCR Signaling Pathway—HRAS—thyroid cancer	0.000114	0.00156	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000112	0.00154	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TRIM33—thyroid cancer	0.000112	0.00153	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CALCA—thyroid cancer	0.000111	0.00152	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—MINPP1—thyroid cancer	0.00011	0.00151	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—MINPP1—thyroid cancer	0.00011	0.00151	CbGpPWpGaD
Ondansetron—CYP2D6—Biological oxidations—RXRA—thyroid cancer	0.000106	0.00146	CbGpPWpGaD
Ondansetron—CYP2C9—Biological oxidations—RXRA—thyroid cancer	0.000105	0.00144	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—TSHR—thyroid cancer	0.000105	0.00144	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000103	0.00141	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CALCB—thyroid cancer	0.000102	0.0014	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—TSHR—thyroid cancer	0.000102	0.0014	CbGpPWpGaD
Ondansetron—OPRM1—TCR Signaling Pathway—AKT1—thyroid cancer	0.000101	0.00138	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CDK1—thyroid cancer	0.0001	0.00138	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.0001	0.00137	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—HPGD—thyroid cancer	9.79e-05	0.00134	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TRIM33—thyroid cancer	9.66e-05	0.00132	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	9.57e-05	0.00131	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—NDUFA13—thyroid cancer	9.36e-05	0.00128	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—NDUFA13—thyroid cancer	9.34e-05	0.00128	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—TSHR—thyroid cancer	9.26e-05	0.00127	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—PRKAR1A—thyroid cancer	9.11e-05	0.00125	CbGpPWpGaD
Ondansetron—CYP1A2—Biological oxidations—RXRA—thyroid cancer	9.01e-05	0.00123	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—SST—thyroid cancer	8.98e-05	0.00123	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—PTCH1—thyroid cancer	8.92e-05	0.00122	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CHST14—thyroid cancer	8.8e-05	0.00121	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—TSHR—thyroid cancer	8.8e-05	0.00121	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CHST14—thyroid cancer	8.78e-05	0.0012	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—CALCA—thyroid cancer	8.64e-05	0.00119	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	8.6e-05	0.00118	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TCF7L1—thyroid cancer	8.46e-05	0.00116	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—SST—thyroid cancer	8.16e-05	0.00112	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—NRG1—thyroid cancer	8.07e-05	0.00111	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—TSHR—thyroid cancer	7.99e-05	0.0011	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—SST—thyroid cancer	7.93e-05	0.00109	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—PTCH1—thyroid cancer	7.87e-05	0.00108	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—PRKAR1A—thyroid cancer	7.86e-05	0.00108	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—CALCA—thyroid cancer	7.85e-05	0.00108	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—MINPP1—thyroid cancer	7.81e-05	0.00107	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—MINPP1—thyroid cancer	7.74e-05	0.00106	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—CALCA—thyroid cancer	7.63e-05	0.00105	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TCF7L1—thyroid cancer	7.47e-05	0.00102	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	7.31e-05	0.001	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—TERT—thyroid cancer	7.24e-05	0.000993	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—SST—thyroid cancer	7.2e-05	0.000987	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—CDK1—thyroid cancer	7.11e-05	0.000974	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—HPGD—thyroid cancer	7.09e-05	0.000972	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—HPGD—thyroid cancer	7.08e-05	0.00097	CbGpPWpGaD
Ondansetron—CYP3A4—Biological oxidations—RXRA—thyroid cancer	6.95e-05	0.000953	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CALCA—thyroid cancer	6.93e-05	0.00095	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—HIF1A—thyroid cancer	6.93e-05	0.000949	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—SST—thyroid cancer	6.84e-05	0.000938	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—PTCH1—thyroid cancer	6.79e-05	0.000931	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—NDUFA13—thyroid cancer	6.64e-05	0.00091	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—MINPP1—thyroid cancer	6.62e-05	0.000907	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—CALCA—thyroid cancer	6.59e-05	0.000903	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—NDUFA13—thyroid cancer	6.58e-05	0.000902	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TCF7L1—thyroid cancer	6.45e-05	0.000884	CbGpPWpGaD
Ondansetron—KCNH2—Neuronal System—HRAS—thyroid cancer	6.35e-05	0.000871	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CDK1—thyroid cancer	6.27e-05	0.00086	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CHST14—thyroid cancer	6.24e-05	0.000856	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—SST—thyroid cancer	6.21e-05	0.000852	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TSHR—thyroid cancer	6.2e-05	0.000849	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CHST14—thyroid cancer	6.19e-05	0.000848	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—NRAS—thyroid cancer	6.1e-05	0.000836	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PRKAR1A—thyroid cancer	6.09e-05	0.000835	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CALCA—thyroid cancer	5.98e-05	0.00082	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MEN1—thyroid cancer	5.82e-05	0.000798	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—BRAF—thyroid cancer	5.73e-05	0.000786	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—NDUFA13—thyroid cancer	5.63e-05	0.000771	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—TPR—thyroid cancer	5.62e-05	0.000771	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PRKAR1A—thyroid cancer	5.53e-05	0.000758	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TSHR—thyroid cancer	5.47e-05	0.000749	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CDK1—thyroid cancer	5.41e-05	0.000742	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PRKAR1A—thyroid cancer	5.38e-05	0.000737	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CHST14—thyroid cancer	5.29e-05	0.000725	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PTCH1—thyroid cancer	5.27e-05	0.000722	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—KRAS—thyroid cancer	5.25e-05	0.00072	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MEN1—thyroid cancer	5.14e-05	0.000705	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—MINPP1—thyroid cancer	5.11e-05	0.0007	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—HPGD—thyroid cancer	5.03e-05	0.00069	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—HPGD—thyroid cancer	4.99e-05	0.000684	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—SST—thyroid cancer	4.82e-05	0.00066	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TSHR—thyroid cancer	4.72e-05	0.000647	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PTCH1—thyroid cancer	4.65e-05	0.000637	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PRKAR1A—thyroid cancer	4.64e-05	0.000636	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CALCA—thyroid cancer	4.64e-05	0.000636	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—HRAS—thyroid cancer	4.46e-05	0.000612	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MEN1—thyroid cancer	4.44e-05	0.000608	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NDUFA13—thyroid cancer	4.34e-05	0.000595	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—AKT1—thyroid cancer	4.34e-05	0.000595	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—HPGD—thyroid cancer	4.26e-05	0.000584	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—SST—thyroid cancer	4.25e-05	0.000583	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—SLC5A5—thyroid cancer	4.21e-05	0.000577	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CDK1—thyroid cancer	4.2e-05	0.000575	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CCND1—thyroid cancer	4.19e-05	0.000574	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CALCA—thyroid cancer	4.09e-05	0.000561	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CHST14—thyroid cancer	4.08e-05	0.00056	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—TPR—thyroid cancer	4.07e-05	0.000558	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—TPR—thyroid cancer	4.06e-05	0.000557	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.05e-05	0.000555	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—PTEN—thyroid cancer	4.04e-05	0.000554	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PTCH1—thyroid cancer	4.01e-05	0.00055	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PRKAR1A—thyroid cancer	4.01e-05	0.000549	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PRKAR1A—thyroid cancer	4e-05	0.000548	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—AKT1—thyroid cancer	3.94e-05	0.00054	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CDK1—thyroid cancer	3.7e-05	0.000508	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—SST—thyroid cancer	3.67e-05	0.000503	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—NRAS—thyroid cancer	3.6e-05	0.000494	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—RXRA—thyroid cancer	3.54e-05	0.000485	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CALCA—thyroid cancer	3.53e-05	0.000484	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.46e-05	0.000474	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NRG1—thyroid cancer	3.37e-05	0.000462	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—HPGD—thyroid cancer	3.29e-05	0.000451	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CDK1—thyroid cancer	3.2e-05	0.000438	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—KRAS—thyroid cancer	3.1e-05	0.000425	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—SLC5A5—thyroid cancer	3.05e-05	0.000418	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—SLC5A5—thyroid cancer	3.04e-05	0.000417	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TERT—thyroid cancer	3.03e-05	0.000415	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NRG1—thyroid cancer	2.97e-05	0.000408	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—HIF1A—thyroid cancer	2.89e-05	0.000397	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—TPR—thyroid cancer	2.89e-05	0.000396	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—TPR—thyroid cancer	2.87e-05	0.000393	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	2.84e-05	0.00039	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	2.82e-05	0.000386	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—TP53—thyroid cancer	2.76e-05	0.000378	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TERT—thyroid cancer	2.67e-05	0.000366	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—HRAS—thyroid cancer	2.64e-05	0.000361	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NRG1—thyroid cancer	2.57e-05	0.000352	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—RXRA—thyroid cancer	2.56e-05	0.000351	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—RXRA—thyroid cancer	2.56e-05	0.00035	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.56e-05	0.00035	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HIF1A—thyroid cancer	2.55e-05	0.00035	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—NRAS—thyroid cancer	2.55e-05	0.000349	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—TPR—thyroid cancer	2.45e-05	0.000336	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	2.41e-05	0.00033	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—BRAF—thyroid cancer	2.4e-05	0.000328	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—AKT1—thyroid cancer	2.33e-05	0.000319	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TERT—thyroid cancer	2.3e-05	0.000316	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—NRAS—thyroid cancer	2.25e-05	0.000308	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PPARG—thyroid cancer	2.23e-05	0.000306	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HIF1A—thyroid cancer	2.2e-05	0.000302	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—KRAS—thyroid cancer	2.19e-05	0.000301	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.18e-05	0.000299	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—SLC5A5—thyroid cancer	2.16e-05	0.000297	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—SLC5A5—thyroid cancer	2.15e-05	0.000294	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—BRAF—thyroid cancer	2.11e-05	0.00029	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.01e-05	0.000276	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—NRAS—thyroid cancer	1.94e-05	0.000266	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—KRAS—thyroid cancer	1.94e-05	0.000265	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—TPR—thyroid cancer	1.89e-05	0.000259	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—HRAS—thyroid cancer	1.86e-05	0.000256	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.86e-05	0.000255	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—SLC5A5—thyroid cancer	1.83e-05	0.000251	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—BRAF—thyroid cancer	1.83e-05	0.00025	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—RXRA—thyroid cancer	1.82e-05	0.000249	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—AKT1—thyroid cancer	1.81e-05	0.000249	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—RXRA—thyroid cancer	1.8e-05	0.000247	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PTGS2—thyroid cancer	1.76e-05	0.000241	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.75e-05	0.00024	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CCND1—thyroid cancer	1.75e-05	0.00024	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.72e-05	0.000235	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PTEN—thyroid cancer	1.69e-05	0.000231	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—KRAS—thyroid cancer	1.67e-05	0.000229	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—AKT1—thyroid cancer	1.65e-05	0.000226	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—HRAS—thyroid cancer	1.65e-05	0.000226	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PPARG—thyroid cancer	1.62e-05	0.000222	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PPARG—thyroid cancer	1.61e-05	0.000221	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—AKT1—thyroid cancer	1.6e-05	0.000219	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CCND1—thyroid cancer	1.54e-05	0.000212	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—RXRA—thyroid cancer	1.54e-05	0.000211	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PTEN—thyroid cancer	1.53e-05	0.00021	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NRAS—thyroid cancer	1.51e-05	0.000206	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.5e-05	0.000205	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PTEN—thyroid cancer	1.49e-05	0.000204	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—AKT1—thyroid cancer	1.45e-05	0.000199	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—HRAS—thyroid cancer	1.42e-05	0.000195	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.41e-05	0.000194	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—AKT1—thyroid cancer	1.38e-05	0.000189	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CCND1—thyroid cancer	1.33e-05	0.000183	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NRAS—thyroid cancer	1.33e-05	0.000182	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—KRAS—thyroid cancer	1.3e-05	0.000178	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PTEN—thyroid cancer	1.29e-05	0.000176	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PTGS2—thyroid cancer	1.27e-05	0.000174	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PTGS2—thyroid cancer	1.27e-05	0.000174	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—AKT1—thyroid cancer	1.25e-05	0.000172	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—RXRA—thyroid cancer	1.19e-05	0.000163	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TP53—thyroid cancer	1.15e-05	0.000158	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PPARG—thyroid cancer	1.15e-05	0.000157	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NRAS—thyroid cancer	1.15e-05	0.000157	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—KRAS—thyroid cancer	1.14e-05	0.000157	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PPARG—thyroid cancer	1.14e-05	0.000156	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PTEN—thyroid cancer	1.11e-05	0.000152	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PTEN—thyroid cancer	1.11e-05	0.000152	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—HRAS—thyroid cancer	1.1e-05	0.000151	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TP53—thyroid cancer	1.02e-05	0.000139	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KRAS—thyroid cancer	9.87e-06	0.000135	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—AKT1—thyroid cancer	9.73e-06	0.000133	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PPARG—thyroid cancer	9.72e-06	0.000133	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HRAS—thyroid cancer	9.72e-06	0.000133	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PTGS2—thyroid cancer	9.03e-06	0.000124	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PTGS2—thyroid cancer	8.95e-06	0.000123	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—AKT1—thyroid cancer	8.83e-06	0.000121	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TP53—thyroid cancer	8.77e-06	0.00012	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—AKT1—thyroid cancer	8.58e-06	0.000118	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HRAS—thyroid cancer	8.39e-06	0.000115	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PTEN—thyroid cancer	7.87e-06	0.000108	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PTEN—thyroid cancer	7.81e-06	0.000107	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PTGS2—thyroid cancer	7.65e-06	0.000105	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PPARG—thyroid cancer	7.5e-06	0.000103	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—AKT1—thyroid cancer	7.41e-06	0.000102	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PTEN—thyroid cancer	6.67e-06	9.14e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—AKT1—thyroid cancer	6.4e-06	8.77e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—AKT1—thyroid cancer	6.38e-06	8.75e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTGS2—thyroid cancer	5.9e-06	8.09e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTEN—thyroid cancer	5.15e-06	7.06e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—AKT1—thyroid cancer	4.54e-06	6.22e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—AKT1—thyroid cancer	4.5e-06	6.17e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—AKT1—thyroid cancer	3.84e-06	5.27e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—AKT1—thyroid cancer	2.97e-06	4.07e-05	CbGpPWpGaD
